E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Psychological processes [F02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067989 |
E.1.2 | Term | Intellectual disability |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10063844 |
E.1.2 | Term | Autism spectrum disorder |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Exploring the clinical effects and neurophysiological mechanisms of a four-week course of multiple-dose oxytocin treatment in children with Autism Spectrum Disorders with comorbid intellectual disability (age 4-13 years) A primary objective is to measure changes from baseline after oxytocin administration on: • Behavioral measurements of core autism symptoms • Cardio electrophysiological measurements of stress
|
|
E.2.2 | Secondary objectives of the trial |
A secondary objective of the trial is to examine changes from baseline after oxytocin administration on: • Other behavioral outcomes (e.g. sleep quality, adaptive function) The clinical trial also includes exploratory outcome measures examining treatment-mechanistic aspects of the oxytocin treatment: • Oxytocin and cortisol hormonal levels • Other neurophysiological measurements of stress • Microbiome compositions
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Participants eligible for inclusion have to meet all of the following criteria: 1. Children within an age-range of 4 to 13 years old with a clinical multidisciplinary diagnosis of ASD; only prepubertal girls will be included (girls with onset of menstruation during the course of the trial are allowed to continue the treatment). 2. Children must be enrolled in a special need school, more specific a class comprising children with an intellectual disability or meet intellectual disability criteria; a total IQ below 75 and an ABAS score below 70. |
|
E.4 | Principal exclusion criteria |
Participants eligible for this Trial must not meet any of the following criteria: 1. Patient takes anti-epileptic medication or has an active medical problems (e.g., serious liver, renal, or cardiac pathology) which influences the metabolism of oxytocin. 2. Significant hearing or vision impairments. 3. Subjects who have had previous chronic treatment with oxytocin 4. Participation in another clinical trial with IMP. 5. Known hypersensitivity to active substance or ingredients of the nasal spray 6. Patient has a known syndrome that interacts with the reproductive hormonal system (e.g. Prader-Willi or Angelman syndrome) Although not a formal exclusion criterion, use of antibiotics within the last 3 months will be screened for, and if present, stool samples will not be collected from the participant.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The following clinical primary endpoints are specified: Assessment of changes from baseline after oxytocin administration on core autism symptoms using: - The Brief Observation of Social Communication Change (BOSCC) (clinician-rated). - The Autism Treatment Evaluation Checklist (ATEC) (parent (caregiver) and teacher-rated)
Also, the following primary electrophysiological endpoint is specified: Assessment of changes from baseline after oxytocin treatment on electrocardiography (ECG) recordings for the assessment of heart rate variability (HRV) during rest and during social stimulation.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The ATEC will be acquired from the parents (caregivers) at four time points: at baseline (T0), immediately after the four-week treatment (T1), and at the follow-up sessions four weeks (T2) and six months post-treatment (T3). The BOSCC will be taken by the clinicians at three time points: at baseline (T0), immediately after the four-week treatment (T1) and at the first follow-up session; four weeks after the treatment (T2). Teachers will fill in the ATEC at three time points: at baseline (T0), immediately after the four-week treatment (T1), and at the four-week follow-up session (T2). The ECG recordings will be acquired at four time points: at baseline (T0), immediately after the four-week treatment (T1), and at the follow-up sessions four weeks (T2). |
|
E.5.2 | Secondary end point(s) |
The following clinical secondary endpoints are specified: - The Adaptive Behavior Assessment System (ABAS-3) (parent (caregiver)-rated) - The Developmental Behaviour Checklist (DBC) (Flemish version: Vragenlijst over Ontwikkeling en Gedrag, VOG) (parent (caregiver)-rated) - The Perceived Stress Scale (PSS) (parent (caregiver)-rated) - The Child Sleep Hygiene Questionnaire (CSHQ) (parent (caregiver)-rated) - The Repetitive Behavior Scale - Revised (RBS-R) (parent (caregiver)-rated)
Additionally, the trial will also encompass several treatment-mechanistic exploratory outcomes as specified in section E.6.13.1.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The DBC will be assessed from the parents at baseline (T0), and one time as outcome assessment, namely at T3, the 6-month follow-up session. The ABAS will be assessed at the intake. The PSS, CSHQ and RBS-R will be assessed from the parents at four time points: at baseline (T0), immediately after the four-week treatment (T1), and at the follow-up sessions four weeks (T2) and six months post-treatment (T3). Teachers will complete the RBS-R at three time points: at baseline (T0), immediately after the four-week treatment (T1) and at the four weeks follow up (T2).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Next to the efficacy assessment, the trial encompasses the effects of multiple-dose oxytocin on neurophysiological and biological indices. The trial will also include exploratory outcome measures: 1. Oxytocin-induced changes in autonomic nervous system stress neurophysiology (EEG, skin conductance, respiration, ambulant ECG) 2. Oxytocin-induced changes in eye tracking 3. Oxytocin-induced changes in biological samples (oxytocin and cortisol hormonal levels; mouth and gut microbiome).
|
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS: Last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |